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Abstract  
Objective: To evaluate the effect of DHEA supplementation on In-Vitro Fertilisation (IVF) 
outcome as assessed by ovarian response, oocyte developmental competence and live birth 
rates in women predicted to have poor ovarian reserve (OR). The feasibility of conducting a 
large trial is also assessed by evaluating the recruitment rates and compliance of the recruited 
participants with DHEA/placebo intake and follow- up rates.  
 
Study design: A single centre, double blinded, placebo controlled, randomized trial was 
performed over two years with 60 women undergoing in-vitro fertilisation (IVF). Subjects were 
randomized, based on a computer-generated pseudo-random code to receive either DHEA or 
placebo with both capsules having similar colour, size and appearance. 60 women with poor 
OR based on antral follicle count or anti- Mullerian hormone thresholds undergoing IVF were 
recruited. They were randomised to receive DHEA 75 mg/day or placebo for at-least 12 weeks 
before starting ovarian stimulation. They had long protocol using hMG 300 IU/day. Data 
analysed by “intention to treat”. Ovarian response, live birth rates and molecular markers of 
oocyte quality were compared between the study and control groups.  
 
Results: The recruitment rate was 39% (60/154). A total of 52 participants (27 versus 25 in the 
study and placebo groups) were included in the final analysis after excluding eight. While the 
mean (standard deviation) DHEA levels were similar at recruitment (9.4 (5) versus 7.5 (2.4) 
ng/ml; P = 0.1), the DHEA levels at pre-stimulation were higher in the study group than in the 
controls (16.3 (5.8) versus 11.1 (4.5) ng/ml; P < 0.01). The number (median, range) of oocytes 
retrieved (4, 0–18 versus 4, 0–15 respectively; P = 0.54) and live birth rates (7/27, 26% versus 
8/25, 32% respectively; RR (95% CI): 0.74 (0.22-2.48) and mRNA expression of 
developmental biomarkers in granulosa and cumulus cells were similar between the groups.  
 Conclusion: Pre-treatment DHEA supplementation, albeit statistical power in this study is low, 
did not improve the response to controlled ovarian hyperstimulation or oocyte quality or live 




Postponement of childbearing is a worldwide common practice because women prefer to 
pursue higher education and career advancement before making the decision to conceive (1). 
Consequently, there is a marked increase in number of women with subfertility, who seek 
medical interventions to overcome the involuntary childlessness incurred as a result of ovarian 
ageing.  
Ovarian ageing, dictated by a decline in quantity and quality of oocytes within the ovaries (2,3), 
is accountable for the age related decline in fertility (4–7), and of the age related increase in 
adverse pregnancy outcomes such as miscarriage (8,9), and aneuploid pregnancies (10–12).  
Women who suffer from ovarian ageing are more likely to be fast-tracked towards assisted 
reproductive technology (ART) but yet are still at risk of having poor treatment outcome due 
to diminished ovarian reserve leading to poor response to ovarian stimulation. While 
chronological age is a major determinant of ovarian ageing, remarkable variation across 
individuals in the rate of ageing process can be observed due to genetic and environmen- tal 
factors. The pace at which ovarian ageing occurs is determined by the rate of primordial follicle 
initiation, the rate of follicular growth and the rate of follicle turnover (13,14). These processes 
are regulated by a number of intra-ovarian autocrine and paracrine growth regulators and 
gonadotrophic endocrinological control which are theoretically amenable to therapeutic 
intervention with hormonal drugs such as Dehydroepiandrosterone (DHEA) (15,16).  
DHEA, the most abundant steroid hormone in human body, is a weak androgenic steroid 
secreted primarily from zona glomer- ulosa of the adrenal glands, but can also be produced 
from both the ovaries and via peripheral conversion. As DHEA levels have been observed to 
decline gradually, independently of menopausal status (17), it has been proposed as an anti-
ageing medication. DHEA was used for the first time as a supplement prior to ovarian 
stimulation in IVF patients in 2000 (18) and since then a few observational studies have 
reported beneficial effects in terms of improving ovarian response and treatment outcome 
following ART in women with reduced ovarian reserve (18–24). A recent animal study 
performed by our group has demonstrated a positive impact of DHEA supplementation on 
ovine follicular development (25). In this paper, we used the ovarian cortical autograft model 
(26) to determine if DHEA supplementation had an effect on the early stage of folliculogenesis 
in sheep, a mono-ovulatory species in which, like the human, the time taken to complete 
folliculogenesis takes several months. We found that DHEA supplementation can increase the 
rate of primordial follicle initiation and preantral follicular growth histologically (25). The 
underlying mechanisms resulting in this stimulatory effect are unknown but DHEA was 
observed to promote granulosa cell proliferation and enhance the level of AMH protein 
expression in the granulosa cells (25). These findings, along with findings from androgen 
supplement on ovarian follicular development data in other animal species (27– 29) indicate 
that DHEA may potentially have a beneficial role to fight against the effects of ovarian ageing 
in women undergoing IVF treatment.  
Despite these positive animal studies, the evidence supporting a clinical benefit in utilising 
DHEA adjuvant therapy in women with poor ovarian reserve is equivocal. We have recently 
performed a meta-analysis examining this question and of 22 studies available at the time, only 
3 controlled studies were eligible for analysis, which showed no benefit of DHEA 
supplementation on clinical pregnancy or miscarriage rates (30). More recently a few small 
randomised controlled studies, albeit having some methodological weaknesses, have similarly 
reported that DHEA does not improve clinical outcome in women with diminished ovarian 
reserve undergoing IVF treatment (31–34) although it is significant that only one of these 
studies was placebo-controlled and even then the size of this RCT was very small with 16 
participants per treatment arm (31).  
Despite this equivocal experimental evidence, a recent world- wide survey has shown that 26% 
of IVF clinicians add DHEA as adjuvant to IVF treatment protocols in women with low ovarian 
reserve (35). Despite widespread use of DHEA, clinical evidence as well as knowledge 
regarding underlying mechanisms of DHEA on improvement of ovarian response is still 
limited, warranting a well designed and large randomized placebo controlled trial. We 
anticipated the practical difficulty of conducting a robust large trial in women with diminished 
ovarian reserve due to potential limitations in recruiting a large number of eligible subjects and 
therefore have set out to do a pilot trial (DITTO—DHEA Intervention To Treat Ovarian 
ageing—trial) so that we could evaluate the feasibility of conducting a large multicentre study 
as well. The objective of this study was to determine the effect of DHEA on the ovarian 
response during controlled ovarian stimulation and the developmental competence of oocytes 
(oocyte quality) by using molecular and clinical parameters in women predicted to have poor 




Materials and methods 
  
Study design, participants and setting  
The study was a pilot double-blinded, randomised, placebo-controlled trial conducted to 
evaluate whether DHEA supplementation prior to controlled ovarian stimulation increases the 
number of oocytes retrieved, the response to the stimulation protocol and IVF success rates; 
i.e. pregnancy rates, miscarriages, in women predicted to have poor ovarian response. It was a 
single centre trial performed at the Nottingham University Research and Treatment Unit in 
Reproduction (NURTURE), a tertiary university-based IVF clinic, University of Nottingham, 
United Kingdom. Women aged more than 23 years, who were predicted to have diminished 
ovarian reserved determined by antral follicle count scan less than 10 and/or serum Anti-
Mullerian hormone less than 5pmol/L undertaking either IVF or ICSI treatment at the clinic, 
were asked to participate in the study at the time of their initial consultation. Patients had to 
have a regular 21–35days menstrual cycle. The exclusion criteria were women with conditions 
as follow; i) obesity with BMI >35kg/M2, ii) having only single ovary, iii) diagnosed untreated 
hydrosalpinx, endometrial polyp or submucous myoma at beginning of her treatment, iv) 
history of seizure or epilepsy, v) were not enrolled in the study before, vi) diagnosed endocrino- 
logical disorders for example thyroid or adrenal diseases, vii) allergy to DHEA, and viii) treated 
with insulin for diabetic management. Participants were divided into two arms; i) intervention 
arm receiving 75mg DHEA capsule, and ii) control arm receiving placebo capsule, having 
similar appearance, size and colour but without DHEA powder. Both groups were advised to 
take their intervention medicinal products (IMPs) for at least 12 weeks before the egg collection 
procedure (prior to and during controlled ovarian stimulation). The IMPs were supplied from 
the licensed pharmaceutical manufacturer (St. Mary’s Pharmacy, Cardiff, UK) authorised by 
the Medicines and Healthcare products Regulatory Agency (MHRA). A maximum number of 
20 weeks supply of IMP were provided to all subjects.  
Ethical considerations  
The study was approved by the NHS Research Ethics committee (East Midlands-Derby, 
reference number NRES 12/EM/0002), the Medicines and Healthcare products Regulatory 
Agency (MHRA) for using of investigational medicinal product (IMP), and the Nottingham 
University Hospitals Trust Research and Development department. It complied with the GCP 
practice and in agreement with the Declaration of Helsinki 1996, the Medicines for Human 
Use Regulations, Statutory Instrument 2004, and all involved UK laws and regulations. All 
participants were informed regarding treatment involved and possible side effects of the IMP. 
They were allowed at least 24h for making their own decision after consultation with partner 
and family members. In addition, they were always eligible to quit the trial at any time and 
they were informed which allocation treatment they received when the study had been 
completed. Patients or patient groups were not involved in the initial stages of study design. 
However, while the study was being planned, about ten patients expected to have poor ovarian 
response have been informed about the DHEA trial at the time of IVF consultation and all of 
them expressed interest in taking part in the study.  
Randomisation and informed consent  
Women with low AMH (<5 pmol/L) and/or AFC (<10) at the time of initial evaluation (eligible 
participants) were given a DHEA information leaflet and invited to participate in the study. 
Written informed consent was signed at the time of patient initial consultation or other 
following appointment. Age stratified randomisation was performed by computer-based 
random permuted block randomisation, created by the University of Nottingham Clinical Trials 
Unit (CTU). Participants were issued their trial number as well as randomisation number and 
were issued their corresponding IMPs supply from the unblinded pharmacist according to the 
randomisation. They were randomised to receive either capsules of 75 mg DHEA or placebo 
taken orally once daily for at least 12 weeks before and during controlled ovarian stimulation 
until the day before egg collection. The CTU kept the randomisation code while the list of 
patients corresponding to allocated treatment was maintained by the pharmacy. There were 
plans to break the code if any participants developed a serious adverse event (SAE).  
Study outcomes  
The primary outcome was the number of oocytes retrieved at the time of egg collection. 
Biochemical pregnancy rates (positive urine pregnancy test at 2 weeks after embryo transfer), 
clinical pregnancy rates (positive foetal cardiac activity from ultrasonography at 6 weeks 
following embryo transfer), miscarriages, and live birth rates were evaluated as secondary 
outcomes. Other outcome data included duration of ovarian stimulation, gonadotrophin doses, 
serum oestradiol on hCG day, fertilisation rates, cleavage and blastocyst rates. Serum DHEA, 
AMH, and IGF-1 levels at the time of initial evaluation, down regulation scan, and egg 
collection were also evaluated. Moreover, oocyte quality and possible mechanisms of DHEA 
action were evaluated by determining the level of mRNA expression in cumulus and granulosa 
cells of ten markers including gonadotrophin (FSH and LH) receptors, pen- traxin 3 (PTX3), 
hyaluronan synthase 2 (HAS2), cyclooxygenase 2 (PTGS2), BMP antagonist-Gremlin 
(GREM1), and epidermal growth factor (EGF)-like signalling molecules; ampiregulin (AREG) 
epiregulin (EPEG) and betaregulin (BTC) using real-time PCR.  
Study protocol (38)  
Standard long down-regulation protocol for ovarian stimulation was used in all patients. 
Participants commenced GnRH agonist, either nafarelin (Synarel; Pharmacia, UK) or buserelin 
(Aventis Pharma, Kent, UK), approximately seven days prior to the expected first day of 
menstrual cycle (treatment cycle). Participants were reviewed two weeks after commencing 
nafarelin or buserelin to check for down regulation with ultrasound scan and blood test. After 
confirmation of pituitary down regulation (thin endometrium (5 mm), ovarian quiescence 
(follicles 10 mm), and serum oestradiol 200 pmol/L), controlled ovarian stimulation utilising  
300 IU/day of Human Menopausal Gonadotrophin (HMG, Menopur, Ferring, UK) 
subcutaneous injection were started. Blood samples were collected at down-regulation scan 
visit for later AMH, DHEA, and IGF-1 assays. Follicle growth was monitored by transvaginal 
ultrasound scan and serum oestradiol from day 8 of stimulation. An ovulation trigger was given 
by subcutaneous injection of 10000 IU human chorionic gonadotrophin (hCG), Pregnyl 
(Organon Laboratories Ltd, Cambridge, UK) once the follicles met the criteria for ovum pick-
up (OPU) procedure (3 leading follicles size 17 mm). However, if the participants developed 
poor ovarian response (<3 pre-ovulatory follicle response of 14 mm by day 12 of stimulation), 
the ovulation trigger was done when 1–2 lead follicle/s reached the size of 17 mm. IMPs and 
gonodotrophin injection as well as GnRH agonist were continued until the day of hCG 
administration. OPU was performed at 36h following hCG administration.  
Extra blood samples were collected on the day of egg collection for hormonal assays (DHEA, 
AMH and IGF-1). Either conventional in vitro fertilisation (IVF) or intracytoplasmic sperm 
injection (ICSI) was chosen for each participant on the embryologist’s discretion depending on 
recent semen analysis results and past treatment cycle history. All media used during oocyte 
collection, fertilisation and embryo culture period were supplied by Vitrolife Ltd. (Warwick, 
UK). Follicular fluid of the largest follicle was collected and kept separately. Both serum and 
first follicular fluid were centrifuged at 4000 rpm for 5min. The supernatant from both serum 
and follicular fluid samples were store at 20C until assayed. The follicular cell pellet was also 
collected and snap frozen in liquid nitrogen and stored at 80C for later real-time PCR analysis. 
For ICSI patients, all oocytes were denuded using hyaluronic acid solution according to the 
standard procedure but the first cumulus oocyte complex (COC) collected from the largest 
follicle was kept separate from the rest. Oocyte transfer media immediately after the hyaluronic 
drop of the first COC was immediately transferred to the laboratory where the media was 
centrifuged at high speed (>10,000rpm) for 5min. Due to the small quantity of cumulus sample, 
50ml of cumulus in transfer media was diluted in a six volume (300ml) of RNAProtect agent 
(Qiagen, Manchester, UK) for RNA preservation, then snapped frozen in liquid nitrogen and 
stored a 80C for subsequent real- time PCR assays. The ICSI procedure was carried out on all 
metaphase II (MII) oocytes according to standard embryology practice. Fertilised embryos 
were cultured in microdrops under oil using G1/G2 sequential media. Media change from G1 
to G2 was done on day 3 unless embryo transfer was performed. Embryo transfer with one or 
two embryos was performed on day 2, 3 or 5 following the day of egg collection. Extended 
embryo culture and blastocyst transfer were advised to the couple by the embryologist if there 
were 3 or more fertilised oocytes at fertilisation check. The number of embryos transferred was 
based on the age of the patient, quality of the available embryo/s, previous treatment history 
and funding criteria with national health service (NHS) funded patients were allowed only a 
single embryo transfer and self-funded patients could choose a maximum of two embryos for 
transfer. Embryo cryopreservation was done for all surplus good quality embryos (grade 1 or 
2 cleavage stage embryos or grade A or B blastocysts). The study was specifically designed to 
include the first treatment cycle only of each participant. All women undergoing both 
conventional IVF and ICSI treatment were advised to self-administer progesterone pessaries 
(Cyclogest; Alpharma, UK) vaginally 400mg twice daily starting on the second day following 
egg collection until the day of urine pregnancy test or until 8 weeks of gestation, if positive 
pregnancy outcome.  
A positive biochemical pregnancy outcome was confirmed by urine pregnancy test carried out, 
by a participant herself, approximately 14days following the day of embryo transfer. Positive 
clinical pregnancy outcome was defined by positive foetal cardiac activity at 6–7 week 
pregnancy scan. All positive clinical pregnancy outcome participants were contacted for their 
live birth outcome. The baseline characteristics, stimulation and outcome data was collected 
and stored in an electronic database until the randomisation code was broken. Any adverse 
effects reported by participants was also noted.  
Hormone analysis  
Determination of serum DHEA, AMH, IGF-1 and follicular DHEA and AMH was carried out 
by using, enzyme-linked immunosor- bent assays (ELISA) from commercial sources: The 
DHEA ELISA Kit (Demeditec Diagnostices, Kiel, Germany), Human anti-Mullerian Hormone 
(AMH) Elisa Kit (Beckman Couter, Krafeld, Germany), and IGF-1 E20 ELISA (Mediagnost, 
Reutlingen, Germany). All ELISA procedures were performed according to suppliers’ 
instructions (39–41). The intra and inter-assay coefficients of variation for all assays was less 
than 10% and 15% respectively.  
Oestradiol (E2) levels were routinely measured during con- trolled ovarian stimulation to 
monitor ovarian follicular development utilising the automated ARCHITECT oestradiol 
chemiluminescent microparticle immunoassay (CMIA; Abbot Diagnostics, Longford, Ireland). 
Peak E2 value represents the E2 level that was measured in the sample obtained on the day of 
hCG trigger prior to egg collection. Again, the intra and inter-assay variation was less than 
10%.  
Real-time PCR analysis  
Both granulosa cell and cumulus cell frozen pellets were thawed on ice. RNA was extracted 
using the RNeasy
 
Micro Kit (QIAGEN, Manchester, UK) according to the manufacturer’s 
instructions. Instantaneously after, generation of cDNA libraries from resulting RNA elute was 
performed by using the Precision nanoScriptTM
 
Reverse Transcription kit (PrimerDesign Ltd, 
South- ampton, UK) according to the manufacturer’s instructions. All cDNA samples were 
kept at 80
 
C until the real-time quantitative PCR (qPCR) was carried out. Real-time qPCR of 
mRNA expression levels of the following 10 genes; FSH receptor (FSHr), Luteinizing 
hormone/choriogonadotropin receptor (LHCGR), Hyaluronan syn- thase 2 (HAS2), Pentraxin-
related gene (PTX3), Androgen receptor (AR), Prostaglandin-endoperoxide synthase 2 
(PTGS2), Gremlin 1 (GREM1), Amphiregulin (AREG), Betacellulin (BTC), and Epiregulin 
(EREG), was then carried out on both granulosa and cumulus cell samples as batch when the 
clinical phase completed. Human- specific target primers labelled with double-dye hydrolysis 
probe (Taqman) were designed and manufactured by PrimerDesign Ltd (Southampton, UK). 
A 15 ml real-time PCR reaction mixed of cDNA template, PrecisionFASTTM 
dNTP/polymerase/buffer mastermix, primer/probe mix in an opaque BrightWhite 96-well plate 
(Primerdesign, Southampton, UK) was performed in the Applied Biosystems 7500Fast 
Platform (Applied Biosystems, Life technolo- gies Ltd, Paisley, UK). The thermo-cycle 
program used was as follows: Enzyme activation for 2 min at 95
 
C followed by 50 PCR cycles 
consisting of denaturation for 5 s at 95
 
C and an annealing/ extension period of 30 s at 60
 
C. 
The target cycle threshold (Ct) values were analysed in the Microsoft Excel programme (IBM 
Corp, New York, USA) using the 2-∆∆CT
 
method outlined in (42) to calculate relative changes 
in gene expression compared to control (fold change), normalised against two endogenous 
reference genes YWHAZ and B2M. (The reference genes YWHAZ and B2M were selected in 
advance utilising the geNormTM Reference Gene Selection Kit (PrimerDesign Ltd, 
Southampton, UK) as the most stable genes across the treatment and control.)  
Statistical analysis  
The study was planned as a pilot study to investigate the “proof of principle” whether DHEA 
supplementation prior and during ovarian stimulation will improve response and outcomes in 
the participants. The sample size was estimated based on the number of subjects that could be 
recruited over a period of 18 months. Approximately 600 women undergo IVF/ICSI treatment 
at NURTURE over an 18 month period. Considering 20% as predicted poor responders based 
on the inclusion criteria and 50% recruitment rate, the number of subjects that could be 
recruited during the study period was estimated as 60. The size of the effect on the primary 
outcome based on the data generated from this trial was expected to help to estimate the sample 
size for a large multicentre trial.  
Statistical analysis was performed based on intention to treat analysis. Only the first treatment 
cycle following randomisation was analysed. Participants were randomised only once and the 
subsequent frozen/thawed embryo transfer cycle was not counted. If a treatment cycle was 
cancelled because of poor ovarian response or if there was no egg retrieved at all at egg 
collection, the number of oocytes (primary outcome) would be counted as zero. If participants 
had spontaneously conceived during the IMP treat- ment, they were advised to stop medication 
immediately and we assigned the number of oocytes retrieved as the highest number observed 
in the study cohort for primary outcome analysis. In addition, they were also included into the 
positive pregnancy outcome group for secondary analyses.  
Statistical analyses were done using the Statistical Package for the Social Sciences (SPSS 
version 21, Chicago, IL). The number of oocytes were failed to demonstrate a normal 
distribution, therefore the data was expressed as median (interquartile) and the difference 
between groups were evaluated by using the Mann- Whitney U test. Differences in clinical and 
other proportional outcomes were tested by the chi-square test. Numerical data of stimulation, 
hormone and cumulus/follicular cell gene expression were analysed by either the student t-test 
or Mann-Whitney U test when appropriate. A two-tailed P value of <0.05 was defined to 
indicate a statistical significance.   
Results  
 
The participant flow diagram is shown in Fig. 1. During a 2-year recruitment period from May 
2012 to May 2014, a total of 982 women underwent IVF/ICSI cycles. 702 women were 
assessed for eligibility and 154 of them were found eligible and invited to take part in the study. 
60 women agreed to take part in the study giving the recruitment rate of 39%. One woman 
spontaneously conceived before taking medication while 7 participants were lost to follow up 
and therefore, a total of 8 participants were excluded from the study. In 52 included 
participants, 2 women in the treatment group spontaneously conceived after taking DHEA 
medication for approximately 4 and 6 weeks. All 50 participants underwent controlled ovarian 
hyperstimulation (COH) using long agonist protocol, nevertheless, egg collection was 
cancelled in 4 participants due to poor ovarian response: 2 had intrauterine insemination (IUI) 
treatment, 2 cycles were completely cancelled due to poor response. Embryo transfer could not 
be performed in 5 other cycles: 4 cycles resulted in failed fertilisation, and 1 cycle only had an 
immature oocyte, which was not suitable for ICSI treatment (no mature oocyte collected). All 
the 5 cancelled cycles due to poor response were assigned to have zero number of oocytes 
retrieved (primary outcome). Table 1 demonstrates baseline demographic data of the treatment 
and placebo groups. Mean (`Standard Deviation; SD) age of participants was 36.8 ± 3.9 and 
35.2 ± 5.3 years, in the DHEA and placebo group, respectively. The mean baseline antral 
follicle count and serum AMH were 8.2 ± 3.2 and 3.8 ± 3.7pmol/L vs. 8 ± 2.9 and 3.6 ± 
3.1pmol/L respectively, representing low ovarian reserve in both groups. A dissimilarity in 
causes of subfertility were observed (p value <0.05 using chi-square test) but there was no 
significant difference in duration of infertility and other baseline characteristics (patients’ BMI, 
ethnicity, and baseline serum DHEA levels) between the study and control groups.  
Number of oocytes retrieved and stimulation outcome  
The number of oocytes retrieved was similar between both groups (median, range: 4, 0–18 vs. 
4, 0–15, p=0.54; Fig. 2). In addition, doses of gonadotrophin used for ovarian stimulation and 
duration of stimulation were comparable so as the proportion of observed poor response (No 
of oocytes retrieved ≤ 4) to controlled ovarian stimulation (Table 2).  
Secondary embryological and pregnancy outcome (Table 2)  
In terms of embryological data, a similar fertilization rate (64.5 ± 24.9%) was observed 
between the treatment and control (48.0 ± 30.4%) groups although there was a favourable trend 
towards the treatment group (p = 0.052). Nonetheless, the numbers of blastocysts acquired 
were not significantly different resulting in only 16% of grade A blastocyst transfer on day 5 
in each group. In our centre, blastocyst culture was performed when patients have at least 4 
cleavage embryos (3 if the cohort are all top morphological grade embryos), otherwise cleavage 
transfer was done instead on day 2 or 3. With regard to pregnancy outcomes, biochemical 
pregnancy rates, clinical pregnancy rates and miscarriages were not different between the two 
groups. All miscarriages, but 2 in the control group, were in the first trimester. Rate of preterm 
birth were 11% and 4% in both treatment and placebo group, respectively. Overall, there was 
one viable twin pregnancy diagnosed at 6 week scan, in the treatment group. Another 
participant in the treatment group was diagnosed with vanishing twin pregnancy but ended up 
with one singleton born. There were no congenital anomalies observed in all 15 babies born in 
this study.  
The number of single embryo transfer (SET) in the treatment and placebo groups was 9/27 
(33.3%) and 10/25 (40%) respectively and corresponding live birth rates per embryo transfer 
were 3/9 (33.3%) and 5/10 (50%) respectively. Live birth rates per embryo transfer with double 
embryo transfer (DET) in the treatment and placebo groups were 2/13 (15.4%) and 3/8 (37.5%) 
respectively. Logistic regression analysis showed number of embryos trans- ferred did not 
influence the over all live birth rates with odds ratio of DET over SET were 1.1 (95% CI 0.5-
2.43; P = 0.8).  
Hormonal levels and gene expression profiles  
There was no significant difference in baseline (pretreatment) serum DHEA and AMH levels 
between the two groups (Table 3). In the treatment group, an increase in serum DHEA at both 
down regulation (DR) scan (pre-stimulation) and egg collection visits was observed (Baseline 
mean (SD) ng/ml: 9.4(5.0) vs. DR scan 16.4(5.8) vs. egg collection 13.0(7.0); p < 0.05 using 
repeated sample ANOVA). Curiously, a significant increase in serum DHEA over this period 
was also observed in the control group (Baseline 7.5 (2.4) vs. DR scan 11.1 (4.5) ng/ml; p < 
0.05). While the mean increase in DHEA levels in the treatment group at DR scan and at egg 
collection compared to baseline levels were 73.4% and 48% respectively, the corresponding 
increase in the placebo group were 38.3% and 20% respectively. However, the mean serum 
DHEA levels at DR scan and egg collection time points were higher in the treatment group 
compared to control group. In contrast, there were no significant differences in follicular 
DHEA levels measured in the largest follicle at the time of egg collection between two groups 
(9.9 (3.8) vs. 11.5 (5.7), p = 0.26) (Table 3).  
Mean serum AMH levels from patients in both groups followed a similar trend where the levels 
were significantly higher at down regulation and then reached their lowest value at the egg 
collection procedure (Table 3). Neither serum AMH levels at all time points nor follicular 
AMH at egg collection was different between DHEA and placebo groups. Serum IGF-1 levels 
were not different between treatment groups and remained stable throughout the experiment. 
Moreover, there was no increase in peak serum E2 and endometrial thickness on the hCG day 
following DHEA supplementation when compared to the placebo group (Table 3).  
Comparison of mRNA expression levels for target genes in cumulus (Fig. 3) and granulosa 
(Fig. 4) cells from ovulatory follicles revealed no differences between the treatment and control 
groups. For ICSI patients, there was no significant alteration in 8 cumulus mRNA expressions, 
including Ar, PTGS2, HAS2, PTX3, GREM1, AREG, EREG, and BTC, in DHEA group when 
compared to the control (P > 0.05 determined by Mann Whitney U test). There was a significant 
amplification failure of FSHr and LHr gene expression and a direct comparison could not 
therefore be executed. Likewise, gene expression in granulosa cells were similar between both 
treatment and control groups.  
Adverse outcome and compliance  
Adverse effects of 75mg/day DHEA supplementation were considerably low. There was no 
serious adverse reaction (SAR) throughout the research. Three patients in the DHEA group had 
reported side effects, one with non-specific gastro-intestinal (GI) disturbance (nausea) and two 
with androgenic side effects (acne and oily skin). Nonetheless, three patients in the control 
group also reported side effects with two reporting GI symptoms (nausea) and one reporting 
acne and oily skin. All patients with androgenic side effects did not require any further 
treatment and all symptoms resolved after completing their stimulation cycle. Two patients 
with GI disturbance (1 each from both groups) had stopped the medication after taking the trial 
medication for over two weeks but still continued with their controlled ovarian stimulation 
treat- ment. Overall, mean duration of DHEA/Placebo supplementation was 81 days (range 




This is the first double blinded placebo controlled randomise controlled trial evaluating the 
effect of pre-treatment DHEA supplementation in women predicted to have poor response with 
ovarian response as the primary outcome and reporting molecular markers of oocyte quality as 
an outcome measure. The data from this study indicate that DHEA adjuvant treatment does not 
improve the ovarian response and treatment outcome as measured by the number of oocytes 
retrieved, clinical pregnancy rates or live birth rates during IVF treatment with long agonist 
protocol in women predicted to have poor ovarian response. In addition, there was no 
improvement in oocyte quality with DHEA treatment as a panel of 10-genes expression profile, 
molecular markers of oocyte quality, was not different in both cumulus cell and granulosa cell 
samples between DHEA treatment and control groups.  
Despite a better fertilisation rate with marginal significance observed in the treatment group 
(64.5% vs. 48.0%; p = 0.052), there was no difference in either stimulation outcomes (oocyte 
number, days of stimulation and doses of hMG used), or clinical outcomes (pregnancy and 
miscarriage rates) between participants who received DHEA supplementation and who 
received placebo. In fact, the trend was lower pregnancy (RR 0.75; 95% CI: 0.23–2.39) and 
live birth rates (RR 0.74; 95% CI: 0.22–2.48) in the DHEA group compared to the control 
group (Table 2) albeit the difference was not statistically significant. While the results from 
this study agree with other recent similar RCTs (31,32), our study is the first double blinded, 
placebo controlled randomised trial reporting ovarian response as the primary outcome in 
predicted poor responders and therefore with least potential bias. Although the study reported 
by Kara, et al. was a larger RCT, this was not blinded and not placebo controlled as the 
participants in the control group were not having any IMPs (32). While Yeung, et al.'s study 
was blinded and placebo controlled, the sample size was small with only 32 participants in total 
and also the randomisation was using sealed envelopes which may have posed potential bias 
to blinding. Further, the defined primary outcome in this study was antral follicle count after 
12 weeks of DHEA treatment in the study (43). In contrast to our study findings, another RCT 
published by Wiser, et al. reported a higher cumulative live birth rate over two cycles in 33 
women with predicted poor response, although the number of oocytes retrieved and live birth 
rate in the first IVF cycle were similar between the study and control groups. In addition to 
being un-blinded and not placebo controlled, there were other methodological weaknesses with 
randomisation being done using sealed envelopes (24).  
As reported (38), the study was conducted as both a proof of principle RCT with ovarian 
response as a surrogate for clinically important outcomes and as a pilot trial to evaluate the 
feasibility of conducting a large late phase multicentre RCT to test the effect of DHEA on live 
births. While there had been no power calculation to determine sample size because this was a 
planned pilot trial, the data from this trial indicate that there is lack of a positive effect of DHEA 
on IVF outcome and not even a trend and therefore the results do not support the concept of 
using DHEA as an adjunct to IVF for improving treatment outcomes in women predicted to 
have poor ovarian response. However, the successful recruitment, albeit the rate of recruitment 
being only 39%, suggests a definitive large multicentre trial would be feasible, but the lack of 
effect of DHEA on IVF outcome suggests it is a low priority.  
The study utilised ovarian reserve tests (both AFC and AMH) to determine women who are 
predicted to be poor responders based on the data earlier published from our group (44). 
Although younger women (mean age 36 years old) were recruited, participants responded 
poorly to the stimulation protocol (median oocyte number = 4, percentage of patient having 
oocyte 4 = 52%) with an incidence of overall cycle cancellation at 20%. Interestingly, two 
participants in the DHEA group did spontaneously conceive during the treatment period, 
although the numbers are clearly too small to form any causal association with exposure to 
DHEA. It was also interesting that although strict criteria in the use of AMH and AFC as 
predictors of poor response were used, some patients in this group yielded higher number of 
oocytes retrieved that entered into the range of normo-responders (maximum number of oocyte 
retrieved=18). It is therefore possible that the ovarian reserve markers employed in this study 
alone were not able to detect patients with a true low ovarian reserve and this may be one of 
the explanations why negative finding were observed in this study. In this regard, this trial had 
been planned before the Bologna criteria were published, so these criteria were not used to 
define the inclusion criteria in this study (45).  
While there may be criticism on the use of long agonist protocol for predicted poor responders 
in our study, instead of short agonist or antagonist protocol, there is no evidence to support the 
use of one particular protocol to another in women with low ovarian reserve (46–49). In fact, 
one recent RCT has shown an improved ovarian response with the use of long protocol 
compared to short agonist protocol and similar response in comparison to antagonist protocol 
(49). Further, this study was planned to minimally disrupt our standard clinical practice and 
the NURTURE fertility clinic has been using the long agonist protocol for the majority of 
patients with satisfactory live birth rates of 37.3%, 13.3% in women aged 38– 39 and 40–42, 
respectively (50).  
Another major strength of the current study is that we backed up the clinical findings with 
molecular analysis of cumulus mRNA expression of gonadotrophin receptors (FSHr, LHr), 
androgen receptor (Ar), markers determining oocyte developmental competence; including 
HAS2, PTX3, PTGS2, GREM1, and epidermal growth factors signalling molecules (AREG, 
EREG and BTC) (51–54). Granulosa cell expression of a similar panel of genes was also 
investigated, mainly to try and understand the mechanism of the effect of DHEA on IVF 
treatment. There were no significant up- and down-regulation of these ligands in the DHEA 
group compared to placebo group, hence confirming the observed clinical effects in the study 
that DHEA at the particular dose and duration has no definite effect at the molecular level. In 
addition, neither serum (AMH, IGF-1, oestradiol) nor follicular (DHEA, AMH) hormone 
levels was increased in the treatment group when compared to the control and this result 
contrasts to other findings in which serum AMH and IGF-1 were reported elsewhere in the 
literature to simultaneously increase when DHEA was supplied to the patients (55). The results 
of this study also disagree with earlier results we have published utilizing an animal 
experimental model in which we found that DHEA supplementation significantly increased 
both serum AMH and follicular AMH protein expression (25). These differences, however, 
may be related to the fact that many of these effects in sheep were observed during the earlier 
stages of follicle development when AMH expression levels are high rather than in large 
ovulatory sized oestrogenic follicles in which AMH levels are known to be low (56,57). 
However, the lack of a clinical effect of DHEA treatment in the current experiment may also 
be related to the dose and treatment duration of DHEA, which may need to be altered to 
influence the clinical outcome in women. Further various DHEA preparations from various 
sources are available in the market. In our study, we used micronized DHEA to prepare the 
IMP capsule, so we could ensure the dose of medication prescribed is accurate.  
Participants were advised to strictly take only the IMPs at least 3 months prior to commence 
ovarian stimulation. Even though serum DHEA levels were higher at both down regulation 
scan and egg collection in the treatment group, a significant increase of mean serum DHEA at 
down regulation was also noted in the placebo group. It is important to note that 4 out of 25 
serum samples in the control had raised DHEA at both the down regulation scan and egg 
collection stages; and 3 out of these 4 were pregnant. While participants were instructed to take 
only the IMP (DHEA or Placebo as randomised), we cannot rule out the possibility of some 
women taking exogenous DHEA. However, serum DHEA rising spontaneously through some 
unknown mechanism in these placebo treated controls cannot be excluded as there is very little 
known concerning normal variation of DHEA during women’s natural and stimulated cycles. 
Thus, in addition to the pharmacological actions of DHEA (pharmacodynamics/phar- 
macokinetics) there is a need to identify the specific population who will be benefited and the 
dose and duration of intervention needed before further evaluating DHEA as an intervention 
in standard IVF practice.  
In conclusion, pre-treatment DHEA supplementation doesn't seem to improve the ovarian 
response and IVF outcome as measured by the number of oocytes retrieved, clinical pregnancy 
rates or live birth rates during IVF treatment with long agonist protocol in women predicted to 
have poor ovarian response. In addition, there was no improvement in oocyte quality with 
DHEA treatment as a panel of 10-genes expression profile, molecular markers of oocyte 
quality, was not different in both cumulus cell and granulosa cell samples between the 
treatment and control groups. The data from the study, although statistical power is low, do not 
support the idea of using DHEA as an adjunct to IVF for improving treatment outcome in 
predicted poor responders. While there has been a great deal of attention in the use of pre-
treatment DHEA in predicted poor responders recently, this practice should be restricted to as 
part of large RCTs.  
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Table 1: Baseline characteristics of participants in both treatment and placebo groups 
 DHEA  
n = 27 
Placebo  
n = 25 
P value 













BMI (kg/m2) 24.5 (4.7) 23.7 (3.3) 0.592 
Antral follicle count.    Mean 
(SD) 
8.2 (3.2)  8 (2.9) 0.675 
Serum AMH in pmol/L. 
Mean (SD) 
3.8 (3.7) 3.6 (3.1) 0.844 
Serum DHEA in ng/ml. 
Mean (SD)  
9.4 (5.0) 7.5 (2.4) 0.114 
Duration of infertility in 
months. Mean (SD) 
35.4 (15.1) 36.8 (18.2) 0.758 
Infertility diagnosis n (%)   0.04 
Endometriosis 4 (14%) 5 (20%)  
Low ovarian reserve 5 (18%) 5 (20%)  
Male factor 2 (7.1%) 5 (20%)  
PCOS/anovulation 2 (7.1%) 0  
Tubal factor 1 (3.6%) 5 (20%)  
Unknown 14 (50%) 5 (20%)  
    
 
¶ For placebo group, 2 (8%), 1 (4%), and 1 (4%) were Indian/Pakistani, African British, and 
others race, respectively 
  
Table 2: Comparison of clinical outcomes between treatment and placebo groups 
 DHEA  
(n = 27) 
Placebo  
(n = 25) 
RR (95% CI) P value 
Stimulation outcomes     
NO. of oocytes retrieved  
median (range)  
4 (0-18) 4 (0-15)  0.538* 
Participants with NO. of   
oocyte retrieved <4 
14 (51.9%) 13 (52.0%)  0.991 







Duration of stimulation 
(days): median (range) 
12.5 (10-17) 13 (10-14)  0.810* 
Cycle outcomes     
Fertilisation rate¶ (%) 
mean (SD)  
64.5 (24.9) 48.0 (30.4)  0.052** 
Blastocyst rate¶¶ (%) 
mean percentage (SD) 
36.8 (26.6) 45.1 (32.1)  0.499** 
Grade A blastocyst transfer  4/25 (16%) 4/25 (16%)  0.906 
Cycle cancellation or no 
embryo for transfer 
4/25 (16%) 7/25 (28%)  0.226 
Pregnancy outcomes     
Implantation (Biochemical; 
urine pregnancy test positive)  
10 (37%) 11 (44%) 0.75 (0.24-2.27) 0.609 
Clinical Pregnancy 8 (30%) 9 (36%) 0.75 (0.23-2.39) 0.625 
Miscarriage 3 (11%) 3 (12%) 0.92 (0.17-5.03) 0.920 
Livebirth  7 (26%) 8 (32%) 0.74 (0.22-2.48) 0.629 
           Preterm (<37w) 3 (11%)        1   (4%)  0.565 
           Term 4 (15%) 7 (28%)  
* Mann Whitney ** Student t test 
¶      N= 23 and 22 for treatment and placebo group, respectively. 
¶¶   Blastocyst culture was performed only if number of cleaved embryos was at least 4 (3 if all 
were good morphological grade); n = 12 for each treatment group.    
Table 3: Comparison of serum and follicular hormones between treatment and placebo groups 
Serum hormone Treatment 
mean(SD) 
Control   
mean(SD) 
P value¶  
DHEA (ng/ml)  <0.01 
Pretreatment 9.4 (5.0) 7.5 (2.4) 0.092 
Down regulation Scan 16.3 (5.8)a 11.1 (4.5)b <0.01 
Egg collection 13.0 (7.0)a 9.0 (6.2) <0.01 
AMH (pmol/L)   0.405 
Pretreatment 3.8 (3.7) 3.6 (3.1) 0.782 
Down regulation scan  6.8 (2.8)c 7.0 (5.2)d 0.382 
Egg collection  1.7 (1.7)c 1.8 (1.5)d 0.183 
IGF-1 (ng/ml)    
Pretreatment 183.2 (39.9) 179.7(23.4) 0.734 
Down regulation scan 181.8 (54.6) 179.7 (47.0) 0.896 
Egg collection  185.1 (46.8) 179.5 (44.6) 0.697 
Oestradiol on hCG day 4444 (3004) 5082 (2738) 0.463 
Endometrial thickness 10.5 (3.2) 10.4 (2.6) 0.972 
 
Follicular hormone  
(Mean ± SD) 
Treatment Control P value¶¶  
DHEA 9.9 (3.8) 11.5 (5.7) 0.256 
AMH  6.9 (3.4) 9.2 (2.1) 0.734 
¶ Repeated measure ANOVA for DHEA and AMH to evaluate p value across all time points. 
Independent-samples T test for serum oestradiol and follicular hormonal levels.  
¶¶ Independent-samples T test after log transformation of data.  
a Significant differences of serum DHEA were observed among time points of interest (p<0.05) 
in the treatment group.  
b a significant difference was observed between pretreatment and down regulation scan DHEA 
in the control group (p<0.05).  
c,d significant p values were detected between both pretreatment-down regulation and 





Fig 1. DITTO study flow 
  
 Fig. 2. Number of oocytes retrieved by group allocation. (X=pregnant prior to down 






 Fig. 3. Comparison of 8 cumulus gene expressions of cumulus-oocyte complexes (COCs) 
from the largest follicle at egg collection between treatment and control. Note: Amplification 
failure in all and 50% of samples were observed in LHr and FSHr, respectively. FSHr: FSH 
receptor; LHr: LH receptor; Ar: Androgen receptor; HAS2: Hyaluronan synthase 2; PTGS2: 
Prostaglandin synthase; PTX3: Pentraxin 3; GREM1: Gremlin; AREG: Ampiregulin; EREG: 
Epiregulin; BTC: Betaregulin.  
  
 Fig. 4. Comparison of 10 granulosa gene expressions of granulosa cells from the largest 
follicle at egg collection between treatment and control.Note: FSHr: FSH receptor; LHr: LH 
receptor; Ar: Androgen receptor; HAS2: Hyaluronan synthase 2; PTGS2: Prostaglandin 
synthase; PTX3: Pentraxin 3; GREM1: Gremlin; AREG: Ampiregulin; EREG: Epiregulin; 
BTC: Betaregulin;  
 
